Nektar Therapeutics Crescita futura
Criteri Future verificati 2/6
Si prevede che gli utili di Nektar Therapeutics diminuiranno a 16.9% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 34% all'anno. Si prevede che l'EPS diminuirà di 5% all'anno. Si prevede che il ritorno sul capitale proprio sarà -52.4% in 3 anni.
Informazioni chiave
-16.9%
Tasso di crescita degli utili
-4.99%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 14.4% |
| Tasso di crescita dei ricavi | 34.0% |
| Rendimento futuro del capitale proprio | -52.38% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 13 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 18
NKTR: Future Phase 3 Autoimmune Data Will Drive Upside Repricing Potential
Narrative Update on Nektar Therapeutics The updated analyst price target for Nektar Therapeutics has shifted from a fair value of $165.00 to $192.00 as analysts factor in recent target changes across the Street and revisit assumptions around revenue growth, profit margins, discount rate and future P/E multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around the potential of its lead asset rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as the implications for long term revenue and earnings power.Articolo di analisi • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153
Shareholders might have noticed that Nektar Therapeutics ( NASDAQ:NKTR ) filed its quarterly result this time last...
Aggiornamento della narrazione • May 01
NKTR: Phase 3 Atopic Dermatitis And Alopecia Data Will Drive Future Upside
Analysts have lifted Nektar Therapeutics' fair value estimate from $128.13 to $144.25 as multiple firms raised their price targets, pointing to rezpegaldesleukin data, an expanded Phase 3 plan in atopic dermatitis, and a clearer funding path as key drivers of their updated views. Analyst Commentary Recent Street research on Nektar Therapeutics has focused on rezpegaldesleukin, the planned Phase 3 program in atopic dermatitis, and updated funding assumptions, with several firms updating models and price targets.Aggiornamento della narrazione • Apr 16
NKTR: Future Phase 3 Atopic Dermatitis Data Will Drive Upside Repricing Potential
Analysts have lifted the base case fair value estimate for Nektar Therapeutics from $135 to $165, citing recent Street research that highlights rezpeg data in atopic dermatitis and alopecia, a Phase 3 plan in atopic dermatitis, and a series of higher price targets and upgrades across multiple firms. Analyst Commentary Recent Street research on Nektar Therapeutics has tilted clearly positive, with several firms lifting price targets and highlighting rezpegaldesleukin, or rezpeg, as the key driver for their valuation work.Seeking Alpha • Apr 15
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Summary Nektar Therapeutics is poised for a key catalyst with upcoming REZPEG 52-week maintenance data in Alopecia Areata (AA) before April’s end. My base case model projects REZPEG will achieve a probability-adjusted 28% of patients reaching SALT <20, matching or exceeding low-dose baricitinib efficacy. REZPEG’s benign safety profile and lack of black box warning may offset slightly lower efficacy compared to JAK inhibitors in AA. A positive 52-week readout could drive NKTR shares 30–40% higher, as current valuation barely reflects AA potential. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 01
NKTR: Phase 3 Atopic Dermatitis Program And Data Strength Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been adjusted from $136.43 to $128.13 as analysts factor in updated rezpegaldesleukin Phase 2 data, plans for a Phase 3 atopic dermatitis study, and recent Street research that refines expectations around future sales potential and valuation multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around rezpegaldesleukin, with analysts updating models on the back of Phase 2 atopic dermatitis data, longer term maintenance results and the planned Phase 3 program.Aggiornamento della narrazione • Mar 18
NKTR: Phase 3 Atopic Dermatitis Program Will Drive Future Upside Potential
The analyst fair value estimate for Nektar Therapeutics has shifted from $129.86 to $136.43, as analysts factor in higher modeled sales potential for rezpegaldesleukin in atopic dermatitis and alopecia, along with recent price target increases across several firms tied to progressing Phase 2 data and planned Phase 3 programs. Analyst Commentary Recent Street research around Nektar Therapeutics has focused on rezpegaldesleukin, with pricing models and risk assessments concentrating on its potential role in atopic dermatitis and alopecia as Phase 2 data matures and Phase 3 plans move forward.Aggiornamento della narrazione • Mar 04
NKTR: Rezpeg Durability In Atopic Dermatitis And Alopecia Will Drive Future Upside
Analysts have lifted their price targets on Nektar Therapeutics, with one moving from $105 to $150, citing stronger conviction in Rezpeg's durability data in Atopic Dermatitis and alopecia areata, a clearer financing profile, and a more supportive catalyst path that is reflected in a higher fair value estimate of about $130 per share. Analyst Commentary Bullish Takeaways Bullish analysts point to the 52 week maintenance data from the REZOLVE AD study as reinforcing confidence in Rezpeg's durability, which they see as a key input to their higher fair value estimates.Aggiornamento della narrazione • Feb 18
NKTR: Alopecia Areata Phase 2b Durability Will Drive Future Upside
Analysts have lifted their price target for Nektar Therapeutics by about $9, citing updated views on Rezpeg's durability, deepening clinical responses, and revised fair value assumptions as the key drivers of the change. Analyst Commentary Recent research updates show a cluster of upbeat views on Nektar Therapeutics, centered on Rezpeg's clinical profile and its potential role in Alopecia Areata and other indications.Articolo di analisi • Feb 12
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have had a really impressive month, gaining 81% after a shaky period...Aggiornamento della narrazione • Feb 04
NKTR: Future Alopecia Areata Data Will Drive Upside Repricing Potential
Analysts have raised their fair value estimate for Nektar Therapeutics to $135 from $120, citing revised revenue growth assumptions, a lower future P/E multiple of about 165, and additional upside potential from Rezpeg in Alopecia Areata, which has an estimated $300 million in possible peak sales. Analyst Commentary Recent Street research has leaned positive on Nektar Therapeutics, with bullish analysts pointing to Rezpeg in Alopecia Areata as a key upside driver supporting higher valuation assumptions.Aggiornamento della narrazione • Jan 20
NKTR: Alopecia Areata Phase 2b Data And Fast Track Will Drive Upside
Analysts have lifted their price target on Nektar Therapeutics from US$99 to US$121, citing Rezpeg's Phase 2b Alopecia Areata opportunity, its safety profile, durability potential, and an added 20% probability of success with about US$300m in estimated peak sales. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$121 price target as a reflection of added confidence in Rezpeg's Alopecia Areata opportunity and its potential to contribute meaningfully to Nektar's valuation over time.Aggiornamento della narrazione • Jan 06
NKTR: Phase 2b Alopecia Data And Fast Track Status Will Drive Upside
Analysts have increased their price target for Nektar Therapeutics to $121 from $99, citing updated assumptions around Rezpeg, including new Alopecia Areata Phase 2b expectations, a clean safety profile, durability potential, and added value for future sales. They also highlighted the ongoing impact of Rezpeg related clinical data on how investors frame the separate Lilly litigation.Articolo di analisi • Dec 25
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25%
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders that were waiting for something to happen have been dealt a blow with...Aggiornamento della narrazione • Dec 17
NKTR: Upcoming Phase 2b Data Will Drive Upside Despite Litigation Uncertainty
Analysts have lifted their blended fair value estimate for Nektar Therapeutics from approximately $107 to $114 per share. They cite higher price targets driven by growing confidence in Rezpeg's Phase 2 data, its novel mechanism and safety profile, and incremental modeled peak sales, despite slightly more conservative long term revenue growth assumptions.Aggiornamento della narrazione • Dec 02
NKTR: Late-Stage Clinical Data Will Drive Upside Despite Litigation Delays
Analysts have raised their price target for Nektar Therapeutics from approximately $94 to $107 per share. They cite growing confidence in the commercial potential of Rezpeg following recent positive clinical data and reinforced differentiation from competitors.Aggiornamento della narrazione • Nov 18
NKTR: Positive Phase 2b Data Will Drive Momentum Amid Delayed Litigation
Analysts have raised their price target for Nektar Therapeutics from $69 to $99 per share. They cite recent positive clinical data and a stronger outlook for Rezpeg's competitive position in atopic dermatitis as the reasons for this adjustment.Aggiornamento della narrazione • Nov 03
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Analysts have raised their price target for Nektar Therapeutics to $99, up from $69. This change is attributed to positive Phase 2b study results for rezpegaldesleukin and increased confidence in its commercial potential.Aggiornamento della narrazione • Oct 20
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics' analyst price target has been revised downward from $101.17 to $93.86 per share. Analysts cite recent clinical updates and ongoing litigation developments as key factors influencing their outlook.Aggiornamento della narrazione • Sep 19
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics’ consensus price target has increased to $101.17, driven by positive Phase 2b REZOLVE-AD results for rezpegaldesleukin, which demonstrated robust efficacy and safety in atopic dermatitis, supporting increased conviction in its differentiated clinical and commercial profile. Analyst Commentary Bullish analysts are raising price targets following positive Phase 2b REZOLVE-AD data for rezpegaldesleukin, with all primary and secondary endpoints met and robust efficacy and safety demonstrated in moderate-to-severe atopic dermatitis.Articolo di analisi • Aug 28
Nektar Therapeutics' (NASDAQ:NKTR) 28% Share Price Surge Not Quite Adding Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have continued their recent momentum with a 28% gain in the last month...Articolo di analisi • Jun 11
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders are no doubt pleased to see that the share price has bounced 29% in...Articolo di analisi • May 15
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be
Market forces rained on the parade of Nektar Therapeutics ( NASDAQ:NKTR ) shareholders today, when the analysts...Articolo di analisi • May 11
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's shaping up to be a tough period for Nektar Therapeutics ( NASDAQ:NKTR ), which a week ago released some...Articolo di analisi • Apr 04
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 29% in the...
Nuova narrazione • Apr 03
Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects
Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins.Articolo di analisi • Feb 10
Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 34% in the...Articolo di analisi • Dec 06
Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
It's not a stretch to say that Nektar Therapeutics' ( NASDAQ:NKTR ) price-to-sales (or "P/S") ratio of 2.9x seems quite...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 47 | -409 | -337 | N/A | 9 |
| 12/31/2027 | 37 | -356 | -270 | N/A | 10 |
| 12/31/2026 | 41 | -250 | -186 | N/A | 10 |
| 3/31/2026 | 56 | -158 | N/A | N/A | N/A |
| 12/31/2025 | 55 | -164 | -209 | -209 | N/A |
| 9/30/2025 | 63 | -121 | -190 | -190 | N/A |
| 6/30/2025 | 75 | -122 | -186 | -185 | N/A |
| 3/31/2025 | 87 | -133 | -178 | -177 | N/A |
| 12/31/2024 | 98 | -119 | -177 | -176 | N/A |
| 9/30/2024 | 93 | -168 | -178 | -177 | N/A |
| 6/30/2024 | 93 | -177 | -175 | -175 | N/A |
| 3/31/2024 | 90 | -176 | -189 | -189 | N/A |
| 12/31/2023 | 90 | -276 | -193 | -193 | N/A |
| 9/30/2023 | 88 | -294 | -204 | -203 | N/A |
| 6/30/2023 | 88 | -307 | -245 | -244 | N/A |
| 3/31/2023 | 89 | -415 | -269 | -267 | N/A |
| 12/31/2022 | 92 | -368 | -310 | -304 | N/A |
| 9/30/2022 | 95 | -454 | -409 | -398 | N/A |
| 6/30/2022 | 96 | -525 | -430 | -416 | N/A |
| 3/31/2022 | 103 | -491 | -440 | -424 | N/A |
| 12/31/2021 | 102 | -524 | -428 | -413 | N/A |
| 9/30/2021 | 100 | -495 | -371 | -360 | N/A |
| 6/30/2021 | 105 | -474 | -321 | -311 | N/A |
| 3/31/2021 | 126 | -429 | -322 | -312 | N/A |
| 12/31/2020 | 153 | -444 | -321 | -313 | N/A |
| 9/30/2020 | 163 | -439 | -349 | -340 | N/A |
| 6/30/2020 | 163 | -429 | -368 | -356 | N/A |
| 3/31/2020 | 137 | -460 | -347 | -326 | N/A |
| 12/31/2019 | 115 | -441 | N/A | -329 | N/A |
| 9/30/2019 | 121 | -427 | N/A | -321 | N/A |
| 6/30/2019 | 119 | -424 | N/A | -324 | N/A |
| 3/31/2019 | 1,184 | 657 | N/A | 690 | N/A |
| 12/31/2018 | 1,193 | 681 | N/A | 718 | N/A |
| 9/30/2018 | 1,249 | 746 | N/A | 755 | N/A |
| 6/30/2018 | 1,374 | 903 | N/A | 920 | N/A |
| 3/31/2018 | 321 | -129 | N/A | -98 | N/A |
| 12/31/2017 | 308 | -97 | N/A | -80 | N/A |
| 9/30/2017 | 250 | -105 | N/A | -52 | N/A |
| 6/30/2017 | 133 | -209 | N/A | -173 | N/A |
| 3/31/2017 | 131 | -198 | N/A | -128 | N/A |
| 12/31/2016 | 165 | -154 | N/A | -117 | N/A |
| 9/30/2016 | 167 | -165 | N/A | -140 | N/A |
| 6/30/2016 | 191 | -130 | N/A | -126 | N/A |
| 3/31/2016 | 181 | -134 | N/A | -160 | N/A |
| 12/31/2015 | 231 | -81 | N/A | -73 | N/A |
| 9/30/2015 | 211 | -73 | N/A | -23 | N/A |
| 6/30/2015 | 284 | 6 | N/A | -55 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che NKTR rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che NKTR rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che NKTR rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di NKTR ( 34% all'anno) crescerà più rapidamente del mercato US ( 11.7% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di NKTR ( 34% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che NKTR non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 08:05 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Nektar Therapeutics è coperta da 31 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |
| George Farmer | BMO Capital Markets Equity Research |